Solventum (NYSE:SOLV) Price Target Raised to $100.00

Solventum (NYSE:SOLV) had its target price lifted by Stifel Nicolaus from $90.00 to $100.00 in a research note issued to investors on Thursday morning, Marketbeat reports. The firm currently has a buy rating on the stock.

Other analysts also recently issued reports about the company. BTIG Research upped their target price on Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday. Mizuho set a $113.00 price target on Solventum in a research report on Thursday. Wells Fargo & Company dropped their price target on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 6th. Piper Sandler cut their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Finally, UBS Group upped their price objective on shares of Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday. Seven research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $91.64.

Solventum Stock Up 0.0%

NYSE SOLV opened at $83.00 on Thursday. The company has a current ratio of 1.02, a quick ratio of 0.75 and a debt-to-equity ratio of 1.00. Solventum has a 1-year low of $62.38 and a 1-year high of $90.00. The company has a 50 day moving average of $79.40 and a 200-day moving average of $74.44. The company has a market cap of $14.13 billion, a price-to-earnings ratio of 10.15, a PEG ratio of 1.18 and a beta of 0.60.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. During the same quarter in the prior year, the business posted $1.69 earnings per share. The firm’s quarterly revenue was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, equities research analysts expect that Solventum will post 7.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Solventum

Large investors have recently modified their holdings of the business. CrossGen Wealth LLC acquired a new position in shares of Solventum during the 4th quarter worth $25,000. Measured Wealth Private Client Group LLC acquired a new stake in Solventum in the third quarter valued at about $25,000. Clearstead Trust LLC boosted its stake in Solventum by 61.0% in the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after buying an additional 150 shares in the last quarter. JNBA Financial Advisors boosted its stake in Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after buying an additional 228 shares in the last quarter. Finally, CYBER HORNET ETFs LLC bought a new position in Solventum in the second quarter valued at about $28,000.

Key Stories Impacting Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q2 results exceeded expectations. Solventum reported adjusted earnings of $2.55 per share versus the $1.91 consensus estimate, while revenue of $2.21 billion also topped forecasts. Organic sales increased 9.5%, and revenue grew 2.2% year over year. Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
• Positive Sentiment: Management raised 2026 earnings guidance to $7.10-$7.20 per share, above its previous outlook. Strong cash flow and the company’s share-repurchase activity further support investor sentiment, although some of the quarter’s benefit came from ERP implementation timing. Solventum outlines HIS separation and raises 2026 EPS guide
• Positive Sentiment: Analyst conviction strengthened. Piper Sandler raised its target to $105 and maintained an overweight rating; Wedbush lifted its target to $101 with an outperform rating; and Stifel increased its target to $100 with a buy rating. UBS also reiterated its buy recommendation. UBS Remains a Buy on Solventum Corporation
• Positive Sentiment: Software separation could sharpen the company’s focus. Solventum plans to separate its health information systems business, potentially creating a more focused medical-technology company and unlocking value from the remaining operations. Solventum to hive off healthcare software business

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.